The WACC of Almirall SA (ALM.MC) is 7.4%.
Range | Selected | |
Cost of equity | 7.0% - 8.9% | 7.95% |
Tax rate | 25.0% - 25.0% | 25% |
Cost of debt | 4.0% - 7.0% | 5.5% |
WACC | 6.4% - 8.4% | 7.4% |
Category | Low | High |
Long-term bond rate | 3.1% | 3.6% |
Equity market risk premium | 7.4% | 8.4% |
Adjusted beta | 0.52 | 0.57 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 7.0% | 8.9% |
Tax rate | 25.0% | 25.0% |
Debt/Equity ratio | 0.17 | 0.17 |
Cost of debt | 4.0% | 7.0% |
After-tax WACC | 6.4% | 8.4% |
Selected WACC | 7.4% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
ALM.MC | Almirall SA | 0.17 | 0.62 | 0.55 |
ALK B.CO | ALK-Abello A/S | 0.03 | 0.28 | 0.27 |
APH.L | Alliance Pharma PLC | 0.27 | 0.27 | 0.22 |
BOI.PA | Boiron SA | 0.04 | 0.31 | 0.3 |
DMP.DE | Dermapharm Holding SE | 0.58 | 0.57 | 0.4 |
KARO.ST | Karo Pharma AB | 0.35 | 0.15 | 0.12 |
MITRA.BR | Mithra Pharmaceuticals SA | 15.81 | 0.76 | 0.06 |
RJF.MC | Laboratorio Reig Jofre SA | 0.24 | 0.24 | 0.21 |
ROVI.MC | Laboratorios Farmaceuticos ROVI SA | 0.04 | 0.53 | 0.51 |
VIRP.PA | Virbac SA | 0.11 | 0.38 | 0.35 |
Low | High | |
Unlevered beta | 0.25 | 0.32 |
Relevered beta | 0.28 | 0.36 |
Adjusted relevered beta | 0.52 | 0.57 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALM.MC:
cost_of_equity (7.95%) = risk_free_rate (3.35%) + equity_risk_premium (7.90%) * adjusted_beta (0.52) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.